Crowded psoriasis market cuts Lilly's mirikizumab ambitions

Eli Lilly has walked away from a major indication for its blockbuster hopeful mirikizumab, shelving plans to file it for psoriasis as the market is getting much too congested. 

AbbVie/Allergan merger cleared in EU with brazikumab sell-of...

AbbVie and Allergan’s $63 billion merger has been cleared by European regulators, who have approved the sell-off of pipeline gastrointestinal autoimmune diseases drug brazikumab to AstraZen

AZ buys back rights to Crohn's candidate from Allergan, ahea...

Allergan is selling rights to its Crohn’s disease drug brazikumab back to AstraZeneca in a move to satisfy regulators ahead of its merger with AbbVie.

Allergan says it will shed two drugs as AbbVie takeover loom...

Abivax sets its course on colitis and Crohn’s

French biotech moves on with the late stage drug development, after publishing impressive clinical trial results of ABX464 for treatment of colitis and hinting its potential in Crohn’s dise

Takeda finalises buyout of TiGenix

Japanese pharma giant Takeda has completed its buyout of TiGenix.